MID FRAIL is a 4-year study taking place in 16 centers in seven countries across Europe. It consists of a multimodal exercise and nutritional intervention in pre-frail and frail patients with Diabetes. Supported by the European Union with funding of €6 million, the MID-Frail Study will investigate how a combined nutritional, exercise and educational intervention programme might improve the health and well-being of people over the age of 70 years with type 2 diabetes and who are becoming frail. The MID-Frail study is an open, randomised, multicentre study, with random allocation by clusters (each trial site) to a usual care group or an intervention group. A total of 1,718 subjects will be randomised with each site enrolling on average 14 or 15 subjects. Difference in function after 2 years will be measured by changes in a summary ordinal score on the short physical performance battery (SPPB) of at least one point. Secondary outcomes include daily activities, economic evaluation, and quality of life. The intervention group will take part in a supervised training programme with resistance exercises, alongside a nutritional and educational programme. Outcomes will be assessed against the usual care group, receiving routine diabetes care.


MOPACT is a four-year project funded by the European Commission under the Seventh Framework Programme to provide the research and practical evidence upon which Europe can begin to make longevity an asset for social and economic development. Summary of findings from MOPACT Active Ageing Forum are now available.


Horizon 2020  is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). You can visit the portal http://ec.europa.eu/programmes/horizon2020/en/h2020-section/health-demographic-change-and-wellbeing and read details on other PHCs. On this portal you can also upload the recently revised Work Program for 2016/2017, find participation rules and general information on the access conditions to other European funding sources in the field of research and innovation.


European research activities on healthy ageing, diet and malnutrition




Alzheimer's Disease Neuroimaging Initiative (ADNI) Since 2005, the longitudinal study has been validating the use of biomarkers including blood tests, tests of cerebrospinal fluid, and MRI/ PET imaging for Alzheimer’s disease (AD) clinical trials and diagnosis. ADNI is designed to define biomarkers for use in clinical trials and to determine the best way to measure the treatment effects of AD therapeutics. As the field has evolved, the goal has been expanded to include the use of biomarkers to detect AD at a pre-dementia stage.


Brain Health Registry Program The goal is to accelerate development of effective treatments to slow progression of Alzheimer's disease by recruiting, assessing, and longitudinally monitoring subjects who join this internet-based registry. This website consists of an informed consent form, a series of questionnaires, and on-line neuropsychological tests to obtain information about brain health and function. The Brain Health Registry has over 30,000 members (Nov. 2015) and is expected to keep growing, and facilitate enrollment of subjects in neuroscience studies including clinical Alzheimer's disease treatment trials.


Clinical Trial of a Multifactorial Fall Injury Prevention Strategy in Older Persons. A large, multi-site, multi-intervention trial will test new patient-centered strategies. Each year, 1 out of 3 adults aged 65 and over falls. A third of those falls result in moderate to severe injuries that can lead to further declines in health and loss of independence. Thousands of older adults die each year from such falls as well. To find effective, evidence-based strategies to address the personal and public health burden of these falls, the National Institutes of Health (NIH) and the Patient-Centered Outcomes Research Institute (PCORI) have joined to support a clinical trial to test individually tailored interventions to prevent fall-related injuries. The award, made by the National Institute on Aging (NIA) of the NIH and funded by PCORI as part of the Falls Injuries Prevention Partnership of the two organizations, is expected to total some $30 million over the 5-year project.
The trial will be led by Shalender Bhasin, M.D., Brigham and Women’s Hospital, Harvard Medical School, Boston; Thomas Gill, M.D., Yale School of Medicine, New Haven, Connecticut; and David Reuben, M.D., David Geffen School of Medicine at the University of California, Los Angeles. The team will include more than 100 researchers, stakeholders, patients and their representatives at 10 clinical health system sites across the country. First-year funding of $7.6 million was awarded on June 1, 2014.
The research team plans to enroll 6,000 adults age 75 and older, living in the community, with one or more modifiable risk factors for falls. The first year of the study is a pilot phase, during which many aspects of the intervention will be tested with small numbers of people across 10 clinical sites. If the go-ahead is given by NIA and PCORI to proceed with the study after that, enrollment for the full trial will start in year two and take place over 18 months. The participants will be followed for up to three years.
The primary trial outcome is reduction in serious fall injuries, including non-spinal fractures, joint dislocation, head injuries, lacerations, internal injuries, and hypothermia. Secondary outcomes include reduction in all falls that cause injuries; all falls regardless of injury; indicators of well-being, physical function and disability, and anxiety and depression.
Ten trial sites across the country were chosen to address geographic, rural/urban, academic/nonacademic, and racial/ethnic diversity, and to include a range of health care systems and models of care. The 14 NIA-funded Claude D. Pepper Older Americans Independence Centers, which include the nation’s premier research programs in complex geriatric syndromes, helped to develop the trial protocol and will participate in the study. Some centers will be involved as trial sites, while others will be involved in data analysis and dissemination of the study findings. Data management and analysis will be coordinated by the Yale School of Public Health.


The SPRINTT project (Sarcopenia and physical frailty in older people: multi-component treatment strategies). The SPRINTT project will create an opportunity to agree on the therapeutic indication, endpoints and Clinical Trial methodology which will allow the development of innovative treatments for Sarcopenia, currently an underdiagnosed geriatric condition. This will be the first non-competitive interventional European clinical trial in frail sarcopenic older patients using physical activity as benchmark for future studies with investigational drugs.
The five-year project is the result of a rich multiple collaboration between sixteen major research institutions in the geriatric field across Europe, such as the Università Cattolica del Sacro Cuore (lead), Rome, Italy, Centre Hospitalier Universitaire de Toulouse, France, Univerzita Karlova v Praze, Prague, Czech Republic, Helsingin yliopisto, Helinski, Finland, Servicio Madrileno de Salud, Madrid, Spain, Universitaetsmedizin of Goettingen, Germany, Georg-August-Universitaet-Stiftung Oeffentlichen Rechts, Germany, Université Paris Descartes, Paris, France, Università degli Studi di Firenze, Florence, Italy, Friedrich- Alexander- Universität Erlangen-Nürnberg, Germany , Uniwersytet Jagiellonski, Cracovia, Poland , Istituto Nazionale di Riposo e Cura per Anziani-INRCA, Ancona, Italy.





Open tender for “Study on the silver economy” A new tender for work to the silver economy has been launched by the European Commission DG for Communications Networks, Content and Technology. The tender is seeking to understand the overall potential and conditions for ICT-based innovation relevant to demographic change to drive job creation and growth in the EU. Submission deadline : August 17, 2015.


On June 5, 2015 the EU’s CHAFEA Directorate (Consumers, Health, Agriculture and Food Executive Agency) launched its 3rd Health Programme. It offers grant funding in a range of areas including ageing and specifically “Support for the implementation and scaling up of good practices in the areas of integrated care, frailty prevention, adherence to medical plans and age-friendly communities”. For more information visit the website. Deadline for applications is 15 September 2015.


The EU Joint Programme-Neurodegenerative Disease (JPND) announces annual Calls for proposals to address high priority areas in neurodegenerative disease research. A pre-call announcement, with indicative call topics is anticipated in early Quarter 4 (October) each year. The JPND diseases are: Alzheimer’s disease (AD) and other dementias, Parkinson’s disease (PD) and PD-related disorders, Prion disease, Motor neurone diseases (MND), Huntington’s Disease (HD), Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA).





Page updated November 21, 2016